Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
[HTML][HTML] British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)
CS Haworth, J Banks, T Capstick, AJ Fisher, T Gorsuch… - Thorax, 2017 - thorax.bmj.com
Background Since the publication of the British Thoracic Society (BTS) Guideline on the
'Management of opportunistic mycobacterial infections' in 2000, our understanding of the …
'Management of opportunistic mycobacterial infections' in 2000, our understanding of the …
Epidemiology and clinical impact of major comorbidities in patients with COPD
MC Smith, JP Wrobel - International journal of chronic obstructive …, 2014 - Taylor & Francis
Comorbidities are frequent in chronic obstructive pulmonary disease (COPD) and
significantly impact on patients' quality of life, exacerbation frequency, and survival. There is …
significantly impact on patients' quality of life, exacerbation frequency, and survival. There is …
[HTML][HTML] Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
PE Postmus, KM Kerr, M Oudkerk, S Senan… - Annals of oncology, 2017 - Elsevier
Lung cancer is the leading cause of cancer mortality worldwide with 1.8 million newly
diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are …
diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are …
Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer: American College of …
A Brunelli, AW Kim, KI Berger, DJ Addrizzo-Harris - Chest, 2013 - Elsevier
Background This section of the guidelines is intended to provide an evidence-based
approach to the preoperative physiologic assessment of a patient being considered for …
approach to the preoperative physiologic assessment of a patient being considered for …
[HTML][HTML] 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
J Vansteenkiste, L Crino, C Dooms, JY Douillard… - Annals of …, 2014 - Elsevier
To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …
[HTML][HTML] The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer
JK Field, SW Duffy, DR Baldwin… - Health technology …, 2016 - pmc.ncbi.nlm.nih.gov
BACKGROUND Lung cancer kills more people than any other cancer in the UK (5-year
survival< 13%). Early diagnosis can save lives. The USA-based National Lung Cancer …
survival< 13%). Early diagnosis can save lives. The USA-based National Lung Cancer …
[HTML][HTML] Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J Vansteenkiste, D De Ruysscher, WEE Eberhardt… - Annals of oncology, 2013 - Elsevier
Lung cancer is the leading cause of cancer mortality worldwide, accounting for∼ 1.3 million
deaths each year. Overall incidence and epidemiology data are summarised in the ESMO …
deaths each year. Overall incidence and epidemiology data are summarised in the ESMO …
Non-small-cell lung cancer
In the decade since the last Lancet Seminar on lung cancer there have been advances in
many aspects of the classification, diagnosis, and treatment of non-small-cell lung cancer …
many aspects of the classification, diagnosis, and treatment of non-small-cell lung cancer …
[HTML][HTML] Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
KM Kerr, L Bubendorf, MJ Edelman, A Marchetti… - Annals of …, 2014 - Elsevier
To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The Second …
consensus conferences to focus on specific issues in each type of tumour. The Second …
The current treatment landscape in the UK for stage III NSCLC
M Evison, AstraZeneca UK Limited - British journal of cancer, 2020 - nature.com
For stage III non-small cell lung cancer (NSCLC), approximately a third of patients survive up
to 5 years, with decreasing 5-year survival rates for stage IIIB and stage IIIC disease …
to 5 years, with decreasing 5-year survival rates for stage IIIB and stage IIIC disease …